UNISOUND (09678) signs contract with multiple top-tier hospitals for large-scale projects.

UNISOUND (09678) announced that following the official release of the new generation universal base U2 large model, the company's underlying universal large model comprehensive capabilities have made a significant breakthrough, significantly accelerating the efficiency of model iteration in vertical fields. Recently, relying on the company's many years of accumulated data assets in the medical industry, combined with a deep understanding of various medical business scenarios, the company has released the industry's first professional large model "U2-Med Three Medical Models" for the medical, medical insurance (including commercial insurance), and pharmaceutical fields, further consolidating the company's leading advantage in large models in the medical field. With the above competitive advantages, the company has recently won multiple artificial intelligence medical construction projects in several top-tier Class A hospitals in China, including Beijing Youan Hospital affiliated with Capital Medical University, Shandong Provincial Hospital affiliated with the First Medical University of Shandong, Nanjing Tongren Hospital, and other regional benchmark medical institutions. The landing of the above benchmark projects not only continues to consolidate the company's core competitive advantage in the high-end market competition but also signifies the entry of the company's commercialization of medical large models into a new stage of scale replication. The series of landing orders fully demonstrate that the company's medical large model has formed a mature, complete, standardized, and rapidly scalable delivery system, which can quickly adapt to the intelligent construction needs of different departments and types of hospitals, setting a benchmark example for the commercialization of medical large models in China. In the future, the company will continue to deepen the application and innovation of large models in the medical field, leverage its self-developed AI core technology base to release high token industry value, promote the upgrading of medical large models to industrial infrastructure. At the same time, the company will further enhance its standardized and scalable delivery capabilities, help medical institutions improve quality and efficiency, and consolidate the company's leading position in the commercialization of medical large models.